76 related articles for article (PubMed ID: 9208879)
1. Increasing effectiveness of interferon-alpha for malignancies.
Lindner DJ; Kalvakolanu DV; Borden EC
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-99-S9-104. PubMed ID: 9208879
[TBL] [Abstract][Full Text] [Related]
2. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Pfeffer LM; Dinarello CA; Herberman RB; Williams BR; Borden EC; Bordens R; Walter MR; Nagabhushan TL; Trotta PP; Pestka S
Cancer Res; 1998 Jun; 58(12):2489-99. PubMed ID: 9635566
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo.
Lindner DJ; Borden EC; Kalvakolanu DV
Clin Cancer Res; 1997 Jun; 3(6):931-7. PubMed ID: 9815768
[TBL] [Abstract][Full Text] [Related]
4. Second-generation interferons for cancer: clinical targets.
Borden EC; Lindner D; Dreicer R; Hussein M; Peereboom D
Semin Cancer Biol; 2000 Apr; 10(2):125-44. PubMed ID: 10936063
[TBL] [Abstract][Full Text] [Related]
5. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
Masci P; Olencki T; Wood L; Rybicki L; Jacobs B; Williams B; Faber P; Bukowski R; Tong K; Borden EC
Clin Pharmacol Ther; 2007 Mar; 81(3):354-61. PubMed ID: 17339865
[TBL] [Abstract][Full Text] [Related]
6. [New aspects of interferon therapy in malignant diseases].
Micksche M
Wien Med Wochenschr; 1993; 143(16-17):454-7. PubMed ID: 7505990
[TBL] [Abstract][Full Text] [Related]
7. [Alpha interferons--new therapeutic modalities].
Bajcetić M; Zigon N; Samardzić R; Beleslin DB
Med Pregl; 1998; 51(3-4):135-9. PubMed ID: 9611956
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies.
Thalasila A; Poplin E; Shih J; Dvorzhinski D; Capanna T; Doyle-Lindrud S; Beers S; Goodin S; Rubin E; DiPaola RS
Cancer Chemother Pharmacol; 2003 Aug; 52(2):119-24. PubMed ID: 12768320
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma.
Lingen MW; Polverini PJ; Bouck NP
Cancer Res; 1998 Dec; 58(23):5551-8. PubMed ID: 9850093
[TBL] [Abstract][Full Text] [Related]
10. Hematological malignancies are associated with a lower interferon-a blocking activity than solid tumors.
Karmaniolas K; Dalamaga M; Liatis S; Kaskara A; Rigopoulos A; Migdalis IN
Res Commun Mol Pathol Pharmacol; 2005; 117-118():65-75. PubMed ID: 18426079
[TBL] [Abstract][Full Text] [Related]
11. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
12. Integrin alpha 11 is a novel type I interferon stimulated gene.
Leomil Coelho LF; Mota BE; Sales PC; Marques JT; de Oliveira JG; Bonjardim CA; Peregrino Ferreira PC; Kroon EG
Cytokine; 2006 Mar; 33(6):352-61. PubMed ID: 16697656
[TBL] [Abstract][Full Text] [Related]
13. Update on the antitumor activity of alpha interferon.
Quesda JR
Oncology (Williston Park); 1988 Mar; 2(3):49-54. PubMed ID: 3079324
[TBL] [Abstract][Full Text] [Related]
14. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models.
Streck CJ; Dickson PV; Ng CY; Zhou J; Gray JT; Nathwani AC; Davidoff AM
Clin Cancer Res; 2005 Aug; 11(16):6020-9. PubMed ID: 16115947
[TBL] [Abstract][Full Text] [Related]
15. New developments in interferon therapy.
Tossing G
Eur J Med Res; 2001 Feb; 6(2):47-65. PubMed ID: 11313191
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
17. Effect of interferon-alpha A/D in combination with the Japanese and Chinese traditional herbal medicine juzen-taiho-to on lung metastasis of murine renal cell carcinoma.
Muraishi Y; Mitani N; Yamaura T; Fuse H; Saiki I
Anticancer Res; 2000; 20(5A):2931-7. PubMed ID: 11062703
[TBL] [Abstract][Full Text] [Related]
18. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.
Papageorgiou A; Lashinger L; Millikan R; Grossman HB; Benedict W; Dinney CP; McConkey DJ
Cancer Res; 2004 Dec; 64(24):8973-9. PubMed ID: 15604261
[TBL] [Abstract][Full Text] [Related]
19. Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells.
Schaber JD; Fang H; Xu J; Grimley PM; Rui H
Cancer Res; 1998 May; 58(9):1914-9. PubMed ID: 9581833
[TBL] [Abstract][Full Text] [Related]
20. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
Nicolini A; Carpi A
Biomed Pharmacother; 2005 Jun; 59(5):253-63. PubMed ID: 15913946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
